期刊
TOXICOLOGY LETTERS
卷 217, 期 1, 页码 82-89出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.toxlet.2012.11.021
关键词
Raloxifene; Fatty acid oxidation; Liver; Mitochondria; Peroxisomes; Ovariectomy
类别
资金
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
- Fundacao Araucaria (FA)
- Coordenacao de Aperfeicoamento de Pessoal do Ensino Superior (CAPES)
Estrogen deficiency accelerates the development of several disorders including visceral obesity and hepatic steatosis. The predisposing factors can be exacerbated by drugs that affect hepatic lipid metabolism. The aim of the present work was to determine if raloxifene, a selective estrogen receptor modulator (SERM) used extensively by postmenopausal women, affects hepatic fatty acid oxidation pathways. Fatty acids oxidation was measured in the livers, mitochondria and peroxisomes of ovariectomized (OVX) rats. Mitochondrial and peroxisomal beta-oxidation was inhibited by raloxifene at a concentration range of 2.5-25 mu M. In perfused livers, raloxifene reduced the ketogenesis from endogenous and exogenous fatty acids and increased the beta-hydroxybutyrate/acetoacetate ratio. An increase in (CO2)-C-14 production without a parallel increase in the oxygen consumption indicated that raloxifene caused a diversion of NADH from the mitochondrial respiratory chain to another oxidative reaction. It was found that raloxifene has a strong ability to react with H2O2 in the presence of peroxidase. It is likely that the generation of phenoxyl radical derivatives of raloxifene in intact livers led to the co-oxidation of NADH and a shift of the cellular redox state to an oxidised condition. This change can perturb other important liver metabolic processes dependent on cellular NADH/NAD(+) ratio. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据